Recombinant antibody technologies are rapidly becoming available and showing considerable clinical success. However, the immunogenicity of murine-derived monoclonal antibodies is restrictive in cancer immunotherapy. Humanized antibodies can overcome these problems and are considered to be a promising alternative therapeutic agent. There are several approaches for antibody humanization. In this article we review various methods used in the antibody humanization process.
Get full access to this article
View all access options for this article.
References
1.
RohrbachP, BrodersO, ToleikisL, and DubelS: Therapeutic antibodies and antibody fusion proteins. Biotechnol Genet Eng Rev, 2003; 20:137–163.
2.
DingG, ChenX, ZhuJ, DuesberyNS, ChengX, and CaoB: A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro. Clin Dev Immunol, 2013; 2013:475809.
3.
PrestaLG: Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol, 2008; 20:460–470.
4.
DucancelF, and MullerBH: Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs, 2012; 4:445–457.
5.
ChamesP, VanRM, WeissE, and BatyD: Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol, 2009; 157:220–233.
6.
DotanE, AggarwalC, and SmithMR: Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. PT, 2010; 35:148–157.
7.
PelatT, BedouelleH, ReesAR, CrennellSJ, LefrancMP, and ThullierP: Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol, 2008; 384:1400–1407.
8.
RossiEA, GoldenbergDM, CardilloTM, SteinR, WangY, and ChangCH: Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res, 2008; 68:8384–8392.
9.
KimJH, and HongHJ: Humanization by CDR grafting and specificity-determining residue grafting. Methods Mol Biol, 2012; 907:237–245.
10.
QueenC, SchneiderWP, SelickHE, PaynePW, LandolfiNF, DuncanJF, AvdalovicNM, LevittM, JunghansRP, and WaldmannTA: A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA, 1989; 86:10029–10033.
11.
BeckA, WurchT, BaillyC, and CorvaiaN: Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol, 2010; 10:345–352.
12.
KobayashiH, MatsunagaY, UchiyamaY, NaguraK, and KomatsuY: Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others. Cancer Med, 2013; 2:130–143.
13.
RobakT: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Invest Drugs, 2009; 10:588–596.
14.
SongR, FrancoD, KaoCY, YuF, HuangY, and HoDD: Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol, 2010; 84:6935–6942.
15.
DjuroJ, and and Yow-PinL: Analytical and preparative methods for purification of antibodies. Food Technol Biotechnol, 2001; 39:215–226.
16.
CriscitielloMF, and FlajnikMF: Four primordial immunoglobulin light chain isotypes, including lambda and kappa, identified in the most primitive living jawed vertebrates. Eur J Immunol, 2007; 37:2683–2694.
17.
FinlayWJ, and AlmagroJC: Natural and man-made V-gene repertoires for antibody discovery. Front Immunol, 2012; 3:342.
18.
DengL, LuoM, VelikovskyA, and MariuzzaRA: Structural insights into the evolution of the adaptive immune system. Annu Rev Biophys, 2013; 191:215–242.
19.
DarsleyMJ, and ReesAR: Nucleotide sequences of five anti-lysozyme monoclonal antibodies. EMBO J, 1985; 4:393–398.
20.
ChothiaC, LeskAM, LevittM, AmitAG, MariuzzaRA, PhillipsSE, and PoljakRJ: The predicted structure of immunoglobulin D1.3 and its comparison with the crystal structure. Science, 1986; 233:755–758.
21.
ChothiaC, LeskAM, TramontanoA, LevittM, Smith-GillSJ, AirG, SheriffS, PadlanEA, DaviesD, and TulipWR: Conformations of immunoglobulin hypervariable regions. Nature, 1989; 342:877–883.
22.
ChothiaC, LeskAM, GherardiE, TomlinsonIM, WalterG, MarksJD, LlewelynMB, and WinterG: Structural repertoire of the human VH segments. J Mol Biol, 1992; 227:799–817.
23.
WuS, and CyglerM: Conformation of complementarity determining region L1 loop in murine IgG lambda light chain extends the repertoire of canonical forms. J Mol Biol, 1993; 229:597–601.
24.
TomlinsonIM, CoxJP, GherardiE, LeskAM, and ChothiaC: The structural repertoire of the human V kappa domain. EMBO J, 1995; 14:4628–4638.
25.
ChothiaC, and LeskAM: Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol, 1987; 196:901–917.
26.
ChothiaC, LeskAM, GherardiE, TomlinsonIM, WalterG, MarksJD, LlewelynMB, and WinterG: Structural repertoire of the human VH segments. J Mol Biol, 1992; 227:799–817.
27.
SaliA, and BlundellTL: Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol, 1993; 234:779–815.
28.
GuexN, and PeitschMC: SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis, 1997; 18:2714–2723.
29.
TramontanoA, ChothiaC, and LeskAM: Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins. J Mol Biol, 1990; 215:175–182.
30.
StudnickaGM, SoaresS, BetterM, WilliamsRE, NadellR, and HorwitzAH: Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng, 1994; 7:805–814.
31.
KuglerM, SteinC, SchwenkertM, SaulD, VockentanzL, HuberT, WetzelSK, ScholzO, PluckthunA, HoneggerA, and FeyGH: Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng Des Sel, 2009; 22:135–147.
32.
HardingFA, SticklerMM, RazoJ, and DuBridgeRB: The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs, 2010; 2:256–265.
33.
KrawczykA, ArndtMA, Grosse-HovestL, WeichertW, GiebelB, DittmerU, HengelH, JagerD, SchneweisKE, Eis-HubingerAM, RoggendorfM, and KraussJ: Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci USA, 2013; 110:6760–6765.
34.
CoutoJR, BlankEW, PetersonJA, and CerianiRL: Anti-BA46 monoclonal antibody Mc3: humanization using a novel positional consensus and in vivo and in vitro characterization. Cancer Res, 1995; 55:1717–1722.
35.
HuWG, YinJ, ChauD, NegrychLM, and CherwonogrodzkyJW: Humanization and characterization of an anti-ricin neutralization monoclonal antibody. PLoS One, 2012; 7:e45595.
36.
BowersPM, NebenTY, TomlinsonGL, DaltonJL, AltobellL, ZhangX, MacomberJL, WuBF, ToobianRM, McConnellAD, VerdinoP, ChauB, HorlickRA, and KingDJ: Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation. J Biol Chem, 2013; 288:7688–7696.
37.
FeldmannA, ArndtC, TopferK, StamovaS, KroneF, CartellieriM, KoristkaS, MichalkI, LindemannD, SchmitzM, TemmeA, BornhauserM, EhningerG, and BachmannM: Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells. J Immunol, 2012; 189:3249–3259.
38.
VerhoeyenM, MilsteinC, and WinterG: Reshaping human antibodies: grafting an antilysozyme activity. Science, 1988; 239:1534–1536.
39.
JonesPT, DearPH, FooteJ, NeubergerMS, and WinterG: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1986; 321:522–525.
40.
McConnellAD, SpasojevichV, MacomberJL, KrapfIP, ChenA, ShefferJC, BerkebileA, HorlickRA, NebenS, KingDJ, BowersPM: An integrated approach to extreme thermostabilization and affinity maturation of an antibody. Protein Eng Des Sel, 2013; 26:151–164.
41.
FooteJ, and WinterG: Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol, 1992; 224:487–499.
42.
MakabeK, NakanishiT, TsumotoK, TanakaY, KondoH, UmetsuM, SoneY, AsanoR, and KumagaiI: Thermodynamic consequences of mutations in Vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J Biol Chem, 2008; 283:1156–1166.
43.
ChothiaC, LeskAM, TramontanoA, LevittM, Smith-GillSJ, AirG, SheriffS, PadlanEA, DaviesD, and TulipWR: Conformations of immunoglobulin hypervariable regions. Nature, 1989; 342:877–883.
44.
TiwariA, KhannaN, AcharyaSK, and SinhaS: Humanization of high affinity anti-HBs antibody by using human consensus sequence and modification of selected minimal positional template and packing residues. Vaccine, 2009; 27:2356–2366.
45.
RemyR, StreltsovVA, NewmanJ, PearceLA, WarkKL, and DolezalO: Germline humanization of a murine Abeta antibody and crystal structure of the humanized recombinant Fab fragment. Protein Sci, 2010; 19:299–308.
46.
WuL, WangC, ZhangD, ZhangX, QianW, ZhaoL, WangH, LiB, and GuoY: Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Lett, 2010; 292:208–214.
47.
PadlanEA: A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol Immunol, 1991; 28:489–498.
48.
PedersenJT, HenryAH, SearleSJ, GuildBC, RoguskaM, and ReesAR: Comparison of surface accessible residues in human and murine immunoglobulin Fv domains. Implication for humanization of murine antibodies. J Mol Biol, 1994; 235:959–973.
49.
BarlowDJ, EdwardsMS, and ThorntonJM: Continuous and discontinuous protein antigenic determinants. Nature, 1986; 322:747–748.
50.
NovotnyJ, HandschumacherM, HaberE, BruccoleriRE, CarlsonWB, FanningDW, SmithJA, and RoseGD: Antigenic determinants in proteins coincide with surface regions accessible to large probes (antibody domains). Proc Natl Acad Sci USA, 1986; 83:226–230.
51.
FontayneA, VanhoorelbekeK, PareynI, Van RI, MeiringM, LamprechtS, RoodtJ, DesmetJ, and DeckmynH: Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody, 6B4. Thromb Haemost, 2006; 96:671–684.
52.
StaelensS, DesmetJ, NgoTH, VauterinS, PareynI, BarbeauxP, Van RI, StassenJM, DeckmynH, and VanhoorelbekeK: Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol Immunol, 2006; 43:1243–1257.
53.
ZhangW, FengJ, LiY, GuoN, and ShenB: Humanization of an anti-human TNF-alpha antibody by variable region resurfacing with the aid of molecular modeling. Mol Immunol, 2005; 42:1445–1451.
54.
ChiuWC, LaiYP, and ChouMY: Humanization and characterization of an anti-human TNF-alpha murine monoclonal antibody. PLoS One, 2011; 6:e16373.
55.
ZhuH, YangB, YangX, WangL, XuJ, LiaoC, FengQ, TangH, HuL, ChenZ, and LiY: A novel antibody fragment targeting HAb18G/CD147 with cytotoxicity and decreased immunogenicity. Cancer Biol Ther, 2009; 8:1035–1044.
56.
DePR, IwahashiM, TamuraM, PadlanEA, GonzalesNR, SantosAD, GiulianoM, SchuckP, SchlomJ, and KashmiriSV: Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J Immunol, 2002; 169:3076–3084.
57.
KashmiriSV, DePR, GonzalesNR, and SchlomJ: SDR grafting—a new approach to antibody humanization. Methods, 2005; 36:25–34.
58.
GonzalesNR, PadlanEA, De PascalisR, SchuckP, SchlomJ, and KashmiriSV: SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity. Mol Immunol, 2004; 41:863–872.
59.
TamuraM, MilenicDE, IwahashiM, PadlanE, SchlomJ, and KashmiriSV: Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J Immunol, 2000; 164:1432–1441.
60.
YoonSO, LeeTS, KimSJ, JangMH, KangYJ, ParkJH, KimKS, LeeHS, RyuCJ, GonzalesNR, KashmiriSV, LimSM, ChoiCW, and HongHJ: Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody. J Biol Chem, 2006; 281:6985–6992.
61.
TanP, MitchellDA, BussTN, HolmesMA, AnasettiC, and FooteJ: “Superhumanized” antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J Immunol, 2002; 169:1119–1125.
62.
HwangWY, AlmagroJC, BussTN, TanP, and FooteJ: Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods, 2005; 36:35–42.
63.
MaderA, and KunertR: Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study. PLoS One, 2012; 7:e39063.
64.
HuWG, ChauD, WuJ, JagerS, and NagataLP: Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus. Vaccine, 2007; 25:3210–3214.
65.
LazarGA, DesjarlaisJR, JacintoJ, KarkiS, and HammondPW: A molecular immunology approach to antibody humanization and functional optimization. Mol Immunol, 2007; 44:1986–1998.
66.
Hammond PW VOJJea: A humanized anti-CD30 monoclonal antibody, XmAbTM2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc-receptor binding. Blood (ASH Annu Meeting Abstr), 2005; 106:1470.
67.
LawrenceCE, HammondPW, ZalevskyJ, HortonH, ChuS, KarkiS, DesjarlaisJR, CarmichaelDF: XmAbTM2513, an Fc engineered humanized anti-CD30 monoclonal antibody, has potent in vitro and in vivo activities, and has the potential for treating hematologic malignancies. Blood (ASH Annu Meeting Abstr), 2007; 110:2340.
68.
JespersLS, RobertsA, MahlerSM, WinterG, and HoogenboomHR: Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology, 1994; 12:899–903.
69.
OsbournJ, GrovesM, and VaughanT: From rodent reagents to human therapeutics using antibody guided selection. Methods, 2005; 36:61–68.
70.
ZhangW: Phage display generation of a novel humanized single-chain antibody against brain natriuretic peptide with potent neutralizing activity. Monoclon Antib Immunodiagn Immunother, 2013; 32:187–192.
71.
ZhangQ, ZhangSH, SuMQ, BaoGQ, LiuJY, YiJ, ShenJJ, and HaoXK: Guided selection of an anti-gamma-seminoprotein human Fab for antibody directed enzyme prodrug therapy of prostate cancer. Cancer Immunol Immunother, 2007; 56:477–489.
72.
KimSJ, and HongHJ: Guided selection of human antibody light chains against TAG-72 using a phage display chain shuffling approach. J Microbiol, 2007; 45:572–577.
73.
Dall'AcquaWF, DamschroderMM, ZhangJ, WoodsRM, WidjajaL, YuJ, and WuH: Antibody humanization by framework shuffling. Methods, 2005; 36:43–60.
74.
LiuD, WangC, LiC, ZhangX, ZhangB, MiZ, AnX, and TongY: Production and characterization of a humanized single-chain antibody against human integrin alphav beta3 protein. J Biol Chem, 2011; 286:24500–24507.
75.
ZhengQ, XiaL, WuWL, ZhengZ, HuoY, WuJ, LiuY, YuH, ChenY, LauSY, ChenH, LuoW, and XiaN: Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses. Antimicrob Agents Chemother, 2011; 55:1349–1357.
76.
McConnellAD, DoM, NebenTY, SpasojevicV, MacLarenJ, ChenAP, AltobellLIII, MacomberJL, BerkebileAD, HorlickRA, BowersPM, and KingDJ: High affinity humanized antibodies without making hybridomas; immunization paired with mammalian cell display and in vitro somatic hypermutation. PLoS One, 2012; 7:e49458.
77.
WaldmannH, and HaleG: CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci, 2005; 360:1707–1711.
78.
BernettMJ, KarkiS, MooreGL, LeungIW, ChenH, PongE, NguyenDH, JacintoJ, ZalevskyJ, MuchhalUS, DesjarlaisJR, and LazarGA: Engineering fully human monoclonal antibodies from murine variable regions. J Mol Biol, 2010; 396:1474–1490.
79.
NeubergerMS, and MilsteinC: Somatic hypermutation. Curr Opin Immunol, 1995; 7:248–254.
80.
MaderA, and KunertR: Humanization strategies for an anti-idiotypic antibody mimicking HIV-1 gp41. Protein Eng Des Sel, 2010; 23:947–954.
81.
JayaramN, BhowmickP, and MartinAC: Germline VH/VL pairing in antibodies. Protein Eng Des Sel, 2012; 25:523–529.
82.
BorrasL, GundeT, TietzJ, BauerU, Hulmann-CottierV, GrimshawJP, and UrechDM: Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem, 2010; 285:9054–9066.
